Elranatamab vs Vonsetamig
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline
Elranatamab
Marketed by Pfizer
NCT05014412 · Phase 2 · completed
The study was nonrandomized, open-label, and single-arm, with all 85 treated participants receiving elranatamab and no placebo or active comparator. Its primary endpoint was a clinical safety outcome—grade 2 or higher cytokine release syndrome—and was reported in 12 participants, but the uncontrolled design provides limited evidence of treatment effectiveness.
Next expected readout: December 2026 · NCT06421675 (registry estimate)
Reported efficacy
Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 (Parts 1 and 2: Cycle 1 (28 days)): Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 (Parts 1 and 2: Cycle 1 (28 days)): All Participants 12 Participants (not_applicable)
Result source: NCT05014412
Vonsetamig
Developed by Regeneron Pharmaceuticals
NCT04083534 · Phase 1/2 · completed
This early-stage study gave REGN5459 to 43 people with relapsed or refractory multiple myeloma across a range of doses, with no randomisation, no masking and no comparison group. Its primary measure was dose-limiting toxicity: one such event occurred, a grade 3 drop in blood oxygen at the highest 900 mg dose, the maximum tolerated dose was not reached, and 480 mg was chosen for later study. A study of this shape shows which doses are tolerated, not whether the drug works better than an alternative.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period (Up to 35 Days); Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period (Up to 12 Weeks After the Last Dose); Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period (Up to 12 Weeks After the Last Dose); Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria (Up to Approximately 104 Weeks): Dose-limiting toxicity incidence across the dose-escalation range (3-900 mg): 1 DLT observed in 43 enrolled patients, at the 900 mg dose level (grade 3 hypoxia); maximum tolerated dose not reached, 480 mg selected as the recommended phase 2 dose. (not_applicable)
Result source: NCT04083534
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Elranatamab
- 8bNCT03269136
17 other results
- 32.9 NCT03269136
- 10.2 NCT03269136
- 19.1 NCT03269136
- 1 NCT03269136
- 1 NCT03269136
- 2.9 NCT03269136
- 1.6 NCT03269136
- 7.6 NCT03269136
- 12.7 NCT03269136
- 6.7 NCT03269136
- 10.4 NCT03269136
- 1.6 NCT03269136
- 1.7 NCT03269136
- 1.1 NCT03269136
- 0.7 NCT03269136
- 0.4 NCT03269136
- 18.1 NCT03269136
- Vonsetamig
- —Not reported
OS, median
- Elranatamab
- 32.9bNCT03269136
13 other results
- 14 NCT03269136
- 19.1 NCT03269136
- 1.7 NCT03269136
- 18 NCT03269136
- 14.8 NCT03269136
- 8.3 NCT03269136
- 12.1 NCT03269136
- 16.2 NCT03269136
- 8.1 NCT03269136
- 11.2 NCT03269136
- 8.4 NCT03269136
- 8.2 NCT03269136
- 31.3 NCT03269136
- Vonsetamig
- —Not reported
ORR
- Elranatamab
- 53.3%bNCT05228470
20 other results
- 37.5% NCT05228470
- 60% NCT03269136
- 83.3% NCT03269136
- 66.7% NCT03269136
- 75% NCT03269136
- 50% NCT03269136
- 0% NCT03269136
- 0% NCT03269136
- 0% NCT03269136
- 0% NCT03269136
- 61.5% NCT03269136
- 77.8% NCT03269136
- 0% NCT03269136
- 0% NCT03269136
- 0% NCT03269136
- 0% NCT03269136
- 57.1% NCT03269136
- 0% NCT03269136
- 75% NCT03269136
- 50% NCT04798586
- Vonsetamig
- —Not reported
VGPR or better
- Elranatamab
- —Trial running · NCT05317416
- Vonsetamig
- —Not reported
MRD negativity
- Elranatamab
- —Trial running · NCT05317416
- Vonsetamig
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Elranatamab: 4 of 4 rows · Vonsetamig: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elranatamab |
|---|---|
| Dropout rate | n/a: no completion milestonePart 2A: Dose Level 1a NCT05014412 · Phase 2 show 22 more resultsn/a: no completion milestonePart 2A: Dose Level 2 NCT05014412 · Phase 2 n/a: no completion milestonePhase 1b NCT05228470 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePhase 2 NCT05228470 · Phase 2 · registry result, not featured evidence n/a: no completion milestone1000 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone600 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone360 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone215 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone130 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone80 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone50 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone30 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone10 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone3 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone1 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone0.3 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestone0.1 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestoneQ1W SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestoneQ2W SC NCT03269136 · Phase 1 · registry result, not featured evidence n/a: no completion milestonePart 1C: PF-06863135 + Lenalidomid NCT03269136 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestonePart 1D: PF-06863135 + Pomalidomid NCT03269136 · Phase 1 · registry result, not featured evidence · combination —Part 2A: PF-06863135 SC NCT03269136 · Phase 1 · registry result, not featured evidence 50% NCT04798586 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —Part 2A: Dose Level 1a NCT05014412 · Phase 2 show 22 more results—Part 2A: Dose Level 2 NCT05014412 · Phase 2 —Phase 1b NCT05228470 · Phase 2 · registry result, not featured evidence —Phase 2 NCT05228470 · Phase 2 · registry result, not featured evidence 0%1000 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 33.3%600 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 25%360 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 0%215 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 0%130 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 0%80 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 33.3%50 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%30 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%10 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%3 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%1 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%0.3 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%0.1 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 14.3%Q1W SC NCT03269136 · Phase 1 · registry result, not featured evidence 0%Q2W SC NCT03269136 · Phase 1 · registry result, not featured evidence 0%Part 1C: PF-06863135 + Lenalidomid NCT03269136 · Phase 1 · registry result, not featured evidence · combination 11.1%Part 1D: PF-06863135 + Pomalidomid NCT03269136 · Phase 1 · registry result, not featured evidence · combination —Part 2A: PF-06863135 SC NCT03269136 · Phase 1 · registry result, not featured evidence — NCT04798586 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 91.7%Part 2A: Dose Level 1a NCT05014412 · Phase 2 show 22 more results72.7%Part 2A: Dose Level 2 NCT05014412 · Phase 2 75%Phase 1b NCT05228470 · Phase 2 · registry result, not featured evidence 76.7%Phase 2 NCT05228470 · Phase 2 · registry result, not featured evidence 83.3%1000 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 66.7%600 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 75%360 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 75%215 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 25%130 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 66.7%80 mcg/kg SC NCT03269136 · Phase 1 · registry result, not featured evidence 83.3%50 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 40%30 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%10 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 100%3 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%1 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 33.3%0.3 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 0%0.1 mcg/kg IV NCT03269136 · Phase 1 · registry result, not featured evidence 85.7%Q1W SC NCT03269136 · Phase 1 · registry result, not featured evidence 69.2%Q2W SC NCT03269136 · Phase 1 · registry result, not featured evidence 50%Part 1C: PF-06863135 + Lenalidomid NCT03269136 · Phase 1 · registry result, not featured evidence · combination 88.9%Part 1D: PF-06863135 + Pomalidomid NCT03269136 · Phase 1 · registry result, not featured evidence · combination 80%Part 2A: PF-06863135 SC NCT03269136 · Phase 1 · registry result, not featured evidence 75% NCT04798586 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 22 more resultsthrombocytopenia 100% leukopenia 87.5% neutropenia 87.5% NCT05228470 · Phase 2 · registry result, not featured evidence neutropenia 73.3% anaemia 66.7% covid-19 66.7% NCT05228470 · Phase 2 · registry result, not featured evidence 1000 mcg/kg SC lymphopenia 100% anaemia 83.3% injection site reaction 83.3% NCT03269136 · Phase 1 · registry result, not featured evidence 600 mcg/kg SC cytokine release syndrome 100% injection site reaction 83.3% lymphopenia 83.3% NCT03269136 · Phase 1 · registry result, not featured evidence 360 mcg/kg SC anaemia 100% lymphopenia 100% skin exfoliation 75% NCT03269136 · Phase 1 · registry result, not featured evidence 215 mcg/kg SC lymphopenia 100% anaemia 75% leukopenia 75% NCT03269136 · Phase 1 · registry result, not featured evidence 130 mcg/kg SC anaemia 75% injection site reaction 75% lymphopenia 75% NCT03269136 · Phase 1 · registry result, not featured evidence 80 mcg/kg SC thrombocytopenia 83.3% anaemia 66.7% lymphopenia 66.7% NCT03269136 · Phase 1 · registry result, not featured evidence 50 mcg/kg IV cytokine release syndrome 83.3% thrombocytopenia 66.7% anaemia 50% NCT03269136 · Phase 1 · registry result, not featured evidence 30 mcg/kg IV anaemia 80% cytokine release syndrome 80% fatigue 80% NCT03269136 · Phase 1 · registry result, not featured evidence 10 mcg/kg IV anaemia 100% arthralgia 100% back pain 50% NCT03269136 · Phase 1 · registry result, not featured evidence 3 mcg/kg IV productive cough 66.7% thrombocytopenia 66.7% anaemia 33.3% NCT03269136 · Phase 1 · registry result, not featured evidence 1 mcg/kg IV anaemia 50% arthralgia 50% aspartate aminotransferase increased 50% NCT03269136 · Phase 1 · registry result, not featured evidence 0.3 mcg/kg IV anaemia 66.7% arthralgia 66.7% alanine aminotransferase increased 33.3% NCT03269136 · Phase 1 · registry result, not featured evidence 0.1 mcg/kg IV anaemia 50% aspartate aminotransferase increased 50% hypomagnesaemia 50% NCT03269136 · Phase 1 · registry result, not featured evidence Q1W SC anaemia 85.7% cytokine release syndrome 85.7% injection site reaction 85.7% NCT03269136 · Phase 1 · registry result, not featured evidence Q2W SC cytokine release syndrome 84.6% neutropenia 84.6% thrombocytopenia 76.9% NCT03269136 · Phase 1 · registry result, not featured evidence arthralgia 100% dry skin 100% injection site reaction 100% NCT03269136 · Phase 1 · registry result, not featured evidence · combination fatigue 77.8% neutropenia 77.8% diarrhoea 66.7% NCT03269136 · Phase 1 · registry result, not featured evidence · combination neutropenia 66.7% decreased appetite 46.7% fatigue 46.7% NCT03269136 · Phase 1 · registry result, not featured evidence cytokine release syndrome 100% neutropenia 75% pneumonia 75% NCT04798586 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elranatamab
show 20 more results
show 11 more results
show 9 more results
show 17 more results
show 8 more results
show 18 more results
show 18 more results
show 17 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elranatamab's landscape · Vonsetamig's landscape